Dr Ulrich Dauer joins group from OMEICOS

" /> Dr Ulrich Dauer joins group from OMEICOS

" />

Please login to the form below

Not currently logged in

Germany's Ventaleon names biotech entrepeneur CEO

Dr Ulrich Dauer joins group from OMEICOS

Ulrich DauerGauting, Germany-based pharma firm Ventaleon has appointed Dr Ulrich Dauer - a biotech executive and entrepreneur - as its chief executive officer at a time when the company enters late-stage clinical development.

Dauer has several years of senior executive management experience serving Activaero - a private German pharma firm now owned by Vectura - as its chief strategy officer and subsequently at Berlin-based OMEICOS Therapeutics where he was chief executive officer.

He said: “I know Ventaleon’s technology very well from my time at Activaero and believe that the novel inhaled antiviral agents that Ventaleon is developing has the potential to help patients suffering from serious infections such as influenza to get better, faster.

“I very much look forward to growing the company and advancing it into the next stages of development.”

Prior to his time at Activaero, Dauer founded 4SC AG, a biopharmaceutical company that focuses on cancer treatments, and served as its CEO for fourteen years.

Jean Luechinger, chairman of Ventaleon’s supervisory board, said: “We are very pleased to have Dauer lead Ventaleon.

“He is joining the company at a critical time as it advances into late-stage clinical development.

“With many years of effectively leading biotechs, forming strong collaborations with the pharmaceutical industry and successfully completing major financial transactions, Dauer has the ideal skill set to take Ventaleon to the next stage of growth.”

Dauer succeeds Gerhard Scheuch who will continue to serve as a member of the supervisory board of Ventaleon.

5th June 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...